This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Both parties to this new relationship are committed to excellence in clinicalresearch and patient access to psychedelic medicine with a focus on naturally derived psilocybin. As two emergent complementary medicines, many parallels exist between the medical cannabis industry and the currently developing psychedelic medicine industry.
Oral COVID-19 vaccine being developed as both a standalone vaccine and a booster for people previously vaccinated. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by focusing on developing two therapeutic platforms, today reported that its subsidiary Oravax Medical Inc.
Patients are often left to their own devices when looking into cannabis and cancer, given the lack of clinical evidence, and stigma surrounding the use of the plant as medicine. Individuals who use cannabis-based medications often want to cure their cancer, not just reduce the symptoms that come with the condition. The answer: Maybe!
Desai brings to Ehave the ability to visualize opportunities and execute creative strategic solutions, while developing deep networks and relationships within the industry. Research in the area of mental health has been Dr. Nitin Desai’s passion. Ben Kaplan, CEO of Ehave, Inc. ” About Ehave, Inc. Ehave, Inc. Email: ir@ehave.com.
There is an urgent need for objective, scientifically sound and robust clinicaltrials to support medicinal cannabis and psychedelics (psilocybin, MDMA, LSD, Ketamine). We don’t want to see research fall to the wayside as it has for cannabis, both in Canada and globally. In Canada, mental health issues affect more than 6.7
“We are very pleased with the rapid completion of enrollment achieved by the team at the Centre for Human Drug Research (CHDR) in Leiden, the Netherlands,” said Alexandra Mancini, InMed’s Senior Vice President of ClinicalDevelopment & Regulatory Affairs. Visit [link].
The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients. About RYAH Group, Inc.
The vast majority of the existing research is on how specific cannabinoids kill cancer, but a growing body of work is revealing how the entourage of compounds found in whole-plant cannabis kills cancer. Without increased blood flow, the tumor does not have enough nutrition to sustain its development.
We’re thrilled to be pursuing SalA and progressing research, as we strive for new treatments.”. Importantly, Revixia’s product will be paired with a digital therapeutic being developed by atai company Introspect Digital Therapeutics, with the aim of streamlining preparation, integration, and continued patient engagement. “In
Ohio is currently accepting petitions in an attempt to expand the list of qualifying conditions for medical cannabis. But this has failed in the past and could prevent measures from moving forward this time unless new research could be presented to sway the state medical board’s decision.
The Top Medical Cannabis Research of 2017 A word from Ron Lipsky, Manager of Business Development and International Relations at MGC Pharmaceuticals MGC Pharma is still riding off the success of 2017 as we progress into 2018, with many exciting developments on the horizon.
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?
As medical cannabis emerges from the dark days of prohibition, researchers are finding a wide range of conditions responding successfully to it. clinicalresearch is extremely difficult to conduct. Epilepsy Seizure disorders are on the list of qualifying conditions for most medical cannabis states.
The commission tasked with developing recommendations to improve mental health treatment for veterans concluded: Congress and the executive branch need to promote research into the therapeutic potential of cannabis and psychedelics such as psilocybin mushrooms and MDMA. Research is Limited Due to Many Obstacles.
NM: As someone who has been researching cannabis for decades, how do you feel about the current legalization situation worldwide and in Japan, in particular? Dr. Andrew Weil: I think the trend very clearly is that in most developed countries, cannabis is being made legal first for medical uses and then also for recreational uses.
Research Team to Study the Impact of CBD on Spinal Injury Pain. Professor Luke Henderson is set to be the study’s lead investigator and he explains that the unfortunate truth for more than half of spinal cord injury patients is the development of chronic pain. Dr. Carins is a postdoctoral researcher who completed her Ph.D.
As the medical community delves into the therapeutic potential of cannabis, certain health conditions have emerged as primary candidates for its prescription. THC, the psychoactive component of cannabis, has analgesic properties that can help manage chronic pain conditions, such as neuropathic pain and arthritis.
If this mechanism is forced to be used repeatedly and often, the body does not properly heal or develop. Often, Post-Traumatic Stress Disorder, a debilitating and chronic illness, can develop. About 10 of every 100 women (or 10%) develop PTSD sometime in their lives compared with about 4 of every 100 men (or 4%).
The 29th annual International Cannabinoid Research Society ( ICRS ) symposium, which convened last month in Bethesda, Maryland, featured new developments in CBD science that have far-reaching implications for many areas of medicine. But would tolerance develop with repeated dosing, thereby mitigating CBD ’s hypotensive effect?
The results also provide confidence in the Company’s plan to dedicate resources to advance PD-001 through FDA IND-enabling studies to support Phase 1 and 2 clinical studies. . – July 28, 2021) – PharmaDrug Inc.
federal government is granting a handful of American companies the option to cultivate and study cannabis for medical research purposes. Groff North America is proud to be producing research-grade marijuana, so we can continue growing the field of cannabis-based medicine,” reads an official statement from the company’s website.
Silo Pharma’s notice of allowance paves the way toward clinicaltrials for its psychedelics delivery platform using homing peptides. OTCQB: SILO), a development-stage biopharmaceutical company focused on the therapeutic potential of psychedelics, recently announced that the U.S. Silo Pharma Inc. Looking to the Future.
Research funding is also up, and all of this data influences how we see, think and hear about the plant and its effects. The cannabis research problem. Despite the massive amount of research publications that come out year over year, many of these studies face one or more research design limitations.
.–(BUSINESS WIRE)– Realm of Caring (RoC) , a nonprofit dedicated to cannabinoid research, has appointed Nicolas Schlienz, Ph.D., as its Research Director, a new role in the organization’s leadership. plan to conduct a controlled clinicaltrial to further understand the effects of CBD in epilepsy treatment.
Company has also initiated preclinical studies aimed at treating psychologic and neurologic conditions. PsyBio intends to continue utilizing its resources to rapidly develop and test new drug candidates within this and other psychedelic categories in anticipation of launching future clinicaltrials.
A recent study , funded by the National Institute on Drug Abuse (NIDA) and published in JAMA Network Open , reported a correlation between obtaining a medical marijuana (MMJ) card and developing CUD. Despite being published in a reputable journal, there are questions about the legitimacy of the research. ClinicalTrial Sample Size.
The use of cannabinoids in the treatment of medical conditions offers major opportunities and challenges to anyone operating in the space. Prohibition Partners has identified at least 30 late-stage clinicaltrials using cannabinoid therapeutics, any of which will probably have a large impact on the medicinal cannabis space.
In this comprehensive guide, we are exploring the research on using cannabis for treating Amyotrophic lateral sclerosis (ALS)—a rare neuron disease that targets the motor neurons in the body. Modern science hasn’t found a cure for this condition so far, and the most frequent cause of death is respiratory failure due to muscle decay.
capital markets, negative global economic conditions, potential negative developments in our clinicaltrials or research programs, other negative developments in our business, or unfavorable legislative or regulatory developments. About Bionomics Limited.
Now, Australian researchers think they may have found an answer: taking psilocybin before MRIs. A fascinating new clinicaltrial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. Magic Mushrooms: The Ticket to a Stress-Free MRI?
Psychedelics are quickly emerging as alternative methods of treatment for mental illnesses and neurodegenerative conditions — particularly in countries such as Canada. What’s more, over the coming years psychedelics will continue to gain acceptance for treating these conditions which will also contribute to that market growth.
They describe their goal as “marrying cutting edge cannabis cultivation with biopharmaceutical research and development.” Their state-of-the-art, 28,000 square-foot cultivation lab and custom “tissue propagation” techniques provide raw materials for ongoing research studies. Find Parkinson’s Disease Relief.
Extensive research in the United States and England on cannabis in the 1930s came to a halt with the beginning of World War II and did not pick up again afterwards due to the various laws and regulations that classified the plant as a drug.Legal issuescontinued to inhibit serious study until half a century ago, when Prof.
Ulcerative Colitis is a condition that causes long-lasting inflammation and ulcers (sores) in the innermost lining of the individual’s large intestine and rectum. Crohn’s Disease is also a condition that causes inflammation, but it affects the lining of the digestive tract, which can then spread deeply into the affected tissues. .
What this means for CBN research These results are, in a word, impressive. Sleep is not often the focus of clinicaltrials on cannabis; rather it is often a secondary outcome. A 2021 review examined all 99 of the existing human research studies on CBN and found just eight studies that met stringent criteria for reliable results.
#image_title Cannabis has been increasingly studied for its potential therapeutic benefits in various medical conditions, including skin disorders and skin cancer. Cannabinoids , particularly cannabidiol (CBD), have shown anti-inflammatory effects that can be beneficial for skin conditions such as acne, psoriasis, and eczema.
The developmental condition can be difficult to manage in severe cases, putting the individual and their family members under a great deal of stress. A team of researchers at Tel Aviv University in Tel Aviv, Israel, led by Ph.D. The researchers were able to alleviate the symptoms of autism in animal models using THC-rich cannabis oil.
Pharmaceutical companies use artificial intelligence (AI) to sort through reams of scientific data to find potentially effective active ingredients to be developed into approved drugs. Most of the data came from five states that list these indications as qualifying conditions for the use of medical cannabis. The Upshot.
MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. MMJ International Holdings is developing oral drug products from natural whole plant extract derivatives from the marijuana plant containing THC and CBD. 561-627-9455. 917-562-9610.
#image_title Families affected by Huntington’s Disease (HD) know to well that this hereditary neurodegenerative condition progressively impacts movement, cognition, and behavior, profoundly affecting both patients and their loved ones. But what truly matters is how these improvements translate into real life.
OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with significant unmet need, has appointed Praveen Tyle, Ph.D., SAN DIEGO, CA, July 26, 2021 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. About Skye Bioscience.
In recent years, research has revealed that two of marijuana’s two major cannabinoids — THC and CBD — can interact with the human endocannabinoid system to influence bone healing and regeneration. At the four week mark and beyond, however, this trend reversed, resulting in an increase in new bone development.
Psilocybin is the active ingredient in magic mushrooms and is currently the psychedelic compound with the most scientific research and industry development. Going public in November 2020 on the NEO exchange, the firm has been steadily growing its market cap and development pipeline. Diversified Drug Development.
Acquisition Advances Company’s Strategic Plan Toward a Diversified Novel Drug Development Pipeline in Psychedelics and Medical Cannabis. This is an exciting venture for FSD Pharma that we believe represents a paradigm shift in the development and outlook of our company.”. Strategic Highlights.
We organize all of the trending information in your field so you don't have to. Join 14,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content